For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Novartis AG to Cease Worldwide Development of Afinitor for Hepatocellular Carcinoma
August 14, 2013
- Chugai Paid 18.1 Billion Yen to Healthcare Professionals in 2012
August 13, 2013
- Novartis’s 11-Year Research Grants to 5 Universities Total 1.1 Billion Yen
August 13, 2013
- JPWA Operating Profit Margin at 0.63%, First Gross Profit Margin Rise Since FY2007
August 13, 2013
- MSD Paid 20.8 Billion Yen to Doctors, Medical Institutions in FY2012
August 13, 2013
- Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
- Otsuka Holdings’ Pharmaceutical Sales Rise 14.8%, Global Sales for Abilify Up 21.9% in April-June Period
August 12, 2013
- Novartis Corrects Third-Party Investigation Report on Diovan Studies
August 12, 2013
- DSP to Set Up Regenerative & Cellular Medicine Office for Integrated Management of All Related Functions
August 12, 2013
- AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
- Ethical Drug Sales Down 0.1% in June: Crecon Report
August 9, 2013
- Seikagaku Obtains Favorable Results from PIII Study of Condoliase for Lumbar Disc Herniation, Plans to File NDA in Japan During FY2013
August 9, 2013
- Meiji Seika Pharma Changes New Drug Plan in the CNS Field; Filing and Launch of Asenapine to Take Priority
August 9, 2013
- Sawai Lifts Limit Restrictions on Atelec Generic Supplies
August 8, 2013
- DSP Aims for Better Communications with Wholesalers, Regulators with Tokyo-Osaka Two Head Office System
August 8, 2013
- Top 4 Wholesalers Report Average Price Agreement Rate of 63.4% at End of June, Down 7.5 Points from 2 Years Prior
August 8, 2013
- Takeda to Merge Bio Development Center following Acquisition of Its Operations
August 7, 2013
- Eli Lilly Paid 16.3 Billion Yen in 2012 to Doctors, Medical Institutions
August 7, 2013
- Janssen, Mochida to Comarket Pain Treatment Tramcet Combination Tablets from October
August 6, 2013
- Toyama Chemical Starts Commercial Production at Newly-Established Plant for Injectables
August 6, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…